Azenta 10-K: $149M Goodwill Impairment, Adverse ICFR Opinion, $167M Net Loss
AZTA has more than doubled off its 52-week low of $15.93.
Summary
Azenta's fiscal 2026 10-K shows a $149.1 million non-cash goodwill impairment driving a $167.0 million net loss, and an unremediated account-reconciliation material weakness that drew an adverse auditor opinion on internal controls. Revenue rose 4.7% to $621.7 million, with $506.4 million of cash and securities and no debt.
Key Events · Earnings and Guidance · AZTA
-
Full-Year Revenue $621.7 Million
Fiscal 2026 revenue rose 4.7% to $621.703 million from $593.821 million, with SMS up 6.1% to $344.443 million and Multiomics up 3.0% to $277.260 million.
-
$149.1 Million Goodwill Impairment
A non-cash impairment of $149.083 million ($112.4 million Multiomics, $36.6 million SMS) drove the operating loss to $174.699 million and net loss to $166.985 million, or -$3.70 per diluted share.
-
Adverse Internal-Control Opinion
PwC issued an adverse opinion on ICFR as of September 30, 2026; the account-reconciliation material weakness identified in the March 2025 quarter remains unremediated and caused immaterial misstatements in fiscal 2025 and 2026 interim and annual statements.
-
Balance Sheet and Buyback
Cash, equivalents and restricted cash of $198.3 million plus $308.1 million of marketable securities, no outstanding debt; 4.4 million shares repurchased for $118.2 million in fiscal 2026, with $131.8 million remaining under the 2025 program.
Analysis · AZTA · Technology
The investment case turns on two items in Azenta's fiscal 2026 annual report: a $149.1 million non-cash goodwill impairment that drove a $167.0 million net loss and a $174.7 million operating loss, versus a $26.8 million operating loss a year earlier, and an adverse opinion on internal control over financial reporting from PricewaterhouseCoopers. The account-reconciliation material weakness first identified in the March 2025 quarter is still unremediated as of September 30, 2026, and management concluded disclosure controls were not effective. That keeps a governance overhang on the stock and raises the risk of delayed or restated reporting. The balance sheet is the offset: $198.3 million of cash and restricted cash plus $308.1 million of marketable securities and no debt. During the year the company bought back 4.4 million shares for $118.2 million, with $131.8 million left on the authorization. Revenue grew 4.7% to $621.7 million, but gross margin slipped to 44.2% on weak Automated Stores volumes and Sanger sequencing declines, the same pressures behind the October 5 Multiomics restructuring.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AZTA was trading at $47.09 on NASDAQ in the Technology sector, with a market capitalization of approximately $2B. The 52-week trading range was $15.93 to $50.06. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.